崔理立，男，中共党员，博士，研究员职称，广东医科大学博士生/博士后导师，澳门科技大学博士生导师。广东省青年珠江学者;广东省“扬帆计划”培养高层次人才。

   现任广东医科大学海洋与热带医学学院院长，广东医科大学海洋医药研究院院长，广东省衰老相关心脑疾病重点实验室主任,广东省神经变性疾病与衰老研究医学重点实验室主任,广东医科大学神经病学研究所所长。吉林大学生命科学学院取得生物化学与分子生物学专业硕博学位，吉林大学优秀博士毕业生。2016 年瑞典卡洛琳斯卡医学院交流访学，2020年 11月参加东江干部学院广东省高层次人才研修班学习结业, 2024年参加国家教育行政学院中青年干部培训班结业。市A类高层次人才。首届广东医科大学“先进科技工作者”、广东医科大学“ 优秀研究生导师”;广东医科大学附属医院“登峰学者”;广东医科大学学科攀峰“十佳党员先锋岗”。目前共承担科研项目20余项，其中国家自然科学基金面上和青年项目4项。授权发明专利5项。广东省自然科学二等奖1项(5/10)，贵州省自然科学三等奖1项(35)。承担硕士生博士生课程各1项，培养研究生获国家奖学金7人。

   课题组研究兴趣主要在阿尔茨海默病等神经相关疾病的小胶质细胞相关发病分子机制和干预。率先提出了鼻脑轴脑部给药的新策略，以及鉴定出系列认知障碍治疗新分子靶点等。目前共发表文章70余篇。其中署名通讯作者在Molecular Therapy. Translational Neurodegenration、Aging Cell.Theranostics、Ageing Research Reviews、Journal of Neuroinflammation. Mbio. Critical Care等期刊共发表SCI论文43篇,中科院一区期刊13篇,二区期刊16篇,它引一千余次,目前H指数23。Agingand disease期刊青年编委、3本Frontiers 期刊客座主编、广东医科大学学报编委等，国家自然科学基金、广东省、浙江省、陕西省等国家省市基金项目函审专家，微信科普公众号“小崔和他的小伙伴们”创始人。中国研究型医院学会神经科学专业常务委员、中国研究型医院学会神经再生与修复专业委员会委员、中国老年学和老年医学学会抗衰老分会委员、广东省医学会神经病学分会痴呆学组委员，广东省医院协会科研实验室建设与管理专委会委员等。

 课题组聚焦衰老相关重大神经系统疾病的基础研究与转化。从易感基因出发，在动物、细胞、分子水平系统的探究影响一些重大神经疾病如  阿尔茨海默病发生发展的重要分子机制并进行靶点干预开发。目前主要研究方向（1）抑郁与AD的共同分子特征和相互影响;（2）ApoE等易感基因在AD发病中分子机制和干预;（3）神经胶质细胞中 No-Coding RNA在AD等神经相关疾病中的分子机制。

   课题组公众号小崔和他的小伙伴们

发表论文：

1)YanWang, Jing-Qi Yang, Ting-Ting Hong, Yuan-Hong Sun, Hai-Li Huang, Feng Chen,Xiong-Jin Chen, Hui-Yi Chen, Shan-Shan Dong, Li-Li Cui*(崔理立),Tie-Lin Yang*. RTN4B-mediated suppression of Sirtuin 2 activity amelioratesβ-amyloid pathology and cognitive impairment in Alzheimer's disease mousemodel. Aging Cell .2020. (共同通讯作者) 2020

2)HuiMai, Weihao Fan, Yan Wang, Yujie Cai, Xiaohui Li, Feng Chen, Xiongjin Chen,Jingqi Yang, Pei Tang, Huiyi Chen, Ting Zou, Tingting Hong, Conghua Wan*, BinZhao*, Lili Cui*(崔理立).Intranasal administration of microRNA-146a-5p agomir rescued the pathologicalprocess and cognitive impairment in anAlzheimer’s disease mouse model. MOLTHER-NUCL ACIDS. 2019. Oct. 10.1016/j.omtn.2019.10.002 (通讯作者) 2019

3)YanWang, Jingqi Yang, Tingting Hong, Xiongjin Chen, Lili Cui*(崔理立). SIRT2: Controversy and multiple roles in disease andphysiology.Ageing Res Rev. 2019Sep 7; 55:100961. (唯一通讯) 2019Review

4)FengChen, Yan Wang, Wenying Zhang, Yujie Cai, Tian Zhao, Hui Mai, Shoubao Tao,Wenyan Wei, Jia Li, Xiongjin Chen, Xiaohui Li, Pei Tang, Weihao Fan, JingqiYang, Mingqian Ou, Furong Lu, Zhipeng Lai, Huiyi Chen,Ting Zou, Furong Sun,Yiming Shao*, Lili Cui*(崔理立). A Functional Polymorphism-Mediated Disruption ofEGR1/ADAM10 Pathway Confers the Risk of Sepsis Progression. MBio. 2019Aug 6;10(4). (通讯作者) 2019

5)WeihaoFan, Chunmei Liang, Mingqian Ou, Ting Zou, Furong Sun, Haihong Zhou*, Lili Cui*(崔理立) .MicroRNA-146a isa wide-reaching neuroinflammatory regulator and potential treatment target inneurological diseases. Frontiers inMolecular Neuroscience DOI: 10.3389/fnmol.2020.00090(通讯作者) 2020

6)OuMQ, Fan WH, Sun FR, Jie WX, Lin MJ, Cai YJ, Liang SY, Yu YS, Li MH, Cui LL,Zhou HH.A Systematic Review and Meta-analysis ofthe Therapeutic Effect of Acupuncture on Migraine.FrontNeurol.DOI: 10.3389/fneur.2020.00596. 2020 (通讯作者) 2020

7)JianghaoZhao, Xiaohui Li, Xiongjin Chen ,Yujie Cai, Yan Wang, Wenjing Sun, Hui Mai,Jingqi Yang, Weihao Fan, Pei Tang, Mingqian Ou, Yuan Zhang, Xuemei Huang, BinZhao*, Lili Cui*(崔理立). GRK5 influences the phosphorylation of tauvia GSK3β and contributes to Alzheimer’s disease. J CellPhysiol;234(7):10411-10420. (通讯作者) 2018

8)ShaoY, Zhao T, Zhang W, He J, Lu F, Cai Y, Lai Z, Wei N, Liang C, Liu L, Hong Y,Cheng X, Li J, Tang P, Fan W, Ou M, Yang J, Liu Y, Cui L*(崔理立).Presenceof the apolipoprotein E-ε4 allele is associated with an increased risk ofsepsis progression.Sci Rep. DOI: 10.1038/s41598-020-72616-0. (通讯作者) 2020

9)CuiL(崔理立) , CaiY, Cheng W, Liu G, Zhao J, Cao H, Tao H, Wang Y, Yin M, Liu T, Liu Y, Huang P,Liu Z, Li K, Zhao B. A Novel, Multi-Target Natural Drug Candidate, Matrine,Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice byInhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis. MolNeurobiol. 2017 Apr;54(3):1939-1952. (第一作者) 2017

10)ZhangY, Zhao J, Yin M, Cai Y, Liu S, Wang Y, Zhang X, Cao H, Chen T, Huang P, Mai H,Liu Z, Tao H, Zhao B*, Cui L*(崔理立). The influence of two functional genetic variants of GRK5on tau phosphorylation and their association with Alzheimer's disease risk.Oncotarget. 2017 Aug 16;8(42):72714-72726. (通讯作者) 2017

11)ShaoY, He J, Chen F, Cai Y, Zhao J, Lin Y, Yin Z, Tao H, Shao X, Huang P, Yin M,Zhang W, Liu Z*, Cui L*(崔理立). Association Study Between Promoter Polymorphisms ofADAM17 and Progression of Sepsis.Cell Physiol Biochem. 2016; 39(4): 1247-61. (通讯作者) 2016

12)CuiL (崔理立)#, GaoY#, Xie Y#, Wang Y, Cai Y, Shao X, Ma X, Li Y, Ma G, Liu G, Cheng W, Liu Y, LiuT, Pan Q, Tao H, Liu Z, Zhao B, Shao Y, Li K. An ADAM10 promoter polymorphism is a functional variantin severe sepsis patients and confers susceptibility to the development ofsepsis.Crit Care. 2015 Mar 5;19:73. (第一作者) 2015

13)Chen R, Xu X, Huang L,Zhong W, Cui L*(崔理立). The Regulatory Role of Long NoncodingRNAs in Different Brain Cell Types Involved in Ischemic Stroke. Front MolNeurosci. 2019 Mar 22;12:61. (通讯作者) 2019

14)ShaoY, Shao X, He J, Cai Y, Zhao J, Chen F, Tao H, Yin Z, Tan X, He Y, Lin Y, Li K,Cui L*(崔理立). Thepromoter polymorphisms of receptor for advanced glycation end products wereassociated with the susceptibility and progression of sepsis. Clin Genet. 2017Apr;91(4):564-575. (通讯作者) 2017

15)CuiL (崔理立), ZhangY, Cao H, Wang Y, Teng T, Ma G, Li Y, Li K, Zhang Y. Ferulic acid inhibits the transition of amyloid-β42monomers to oligomers but accelerates the transition from oligomers to fibrils. JAlzheimers Dis. 2013;37(1):19-28. （第一作者）2013

16)XuZhou, Hua Tao*, Yujie Cai, Lili Cui*(崔理立), Bin Zhao, Keshen Li.Stage‐dependent involvement of ADAM10 and its significance in epilepticseizures. J Cell Mol Med. 2019 May 13. doi: 10.1111/jcmm.14307. (并列通讯作者) 2019

17)ShaoY, Chen F, Chen Y, Zhang W, Lin Y, Cai Y, Yin Z, Tao S, Liao Q, Zhao J, Mai H,He Y, He J*, Cui L*(崔理立) . Association between genetic polymorphisms in theautophagy-related 5 gene promoter and the risk of sepsis. SciRep. 2017 Aug 24;7(1):9399. (通讯作者) 2017

18)YanWang, YuJie Cai, Haili Huang, Xiongjin Chen, Xiaoyi Chen, Xiaoting Chen, HuiMai, Xiaohui Li, Jianghao Zhao, Jingqi Yang, Weihao Fan, Pei Tang, Yusen Chen,Keshen Li*, Lili Cui*(崔理立).MiR-486-3p influences the neurotoxicity of a-synuclein by targeting the SIRT2gene and the polymorphisms at target sites contributing to Parkinson’s disease.Cell Physiol Biochem. 2018 Dec 12;51(6):2732-2745. (通讯作者) 2018

19)XiongjinChen, HuiMai, Xiaoting Chen, Yujie Cai, Qiufei Cheng, Xiaoyi Chen, Xiaohui Li,Weihao Fan, Pei Tang, Mingqian Ou, Jingqi Yang, Yusen Chen* and Lili Cui*(崔理立). Rs2015 Polymorphism in miRNA TargetSite of Sirtuin2 Gene Is Associated with the Risk of Parkinson’s Disease inChinese Han Population. BioMed Research International. 2019:1498034. (通讯作者) 2019

20)HuangP, Cai Y, Zhao B*, Cui L*(崔理立). Roles of NUCKS1 in Diseases: Susceptibility, PotentialBiomarker, and Regulatory Mechanisms. Biomed Res Int.2018 Jan 29; 2018: 7969068. (通讯作者) 2018

21)TaoH, Zhao J, Liu T, Cai Y, Zhou X, Xing H, Wang Y, Yin M, Zhong W, Liu Z, Li K,Zhao B, Zhou H*, Cui L*(崔理立). Intranasal Delivery of miR-146a Mimics Delayed SeizureOnset in the Lithium-Pilocarpine Mouse Model. Mediators Inflamm.2017;:6512620.IF: 3.2320. (通讯作者) 2017

22)MoJJ, Liu LY, Peng WB, Rao J, Liu Z*, Cui L*(崔理立). The effectiveness of creatine treatment for Parkinson'sdisease: an updated meta-analysis of randomized controlled trials. BMCNeurol. 2017 Jun 2;17(1):105. (通讯作者) 2017

23)ZhongH, Cai Y, Cheng J, Cai D, Chen L, Su C, Li K, Chen P, Xu J*, Cui L*(崔理立). Apolipoprotein E Epsilon 4 Enhances the Associationbetween the rs2910164 Polymorphism of miR-146a and Risk of AtheroscleroticCerebral Infarction. J Atheroscler Thromb. 2016 Jul 1;23 (7):819-29. (通讯作者) 2016

24)CuiL(崔理立) #, TaoH#, Wang Y#, Liu Z, Xu Z, Zhou H, Cai Y, Yao L, Chen B, Liang W, Liu Y, ChengW, Liu T, Ma G, Li Y, Zhao B, Li K.A functional polymorphism of the microRNA-146a gene isassociated with susceptibility to drug-resistant epilepsy and seizuresfrequency.Seizure. 2015 Apr; 27:60-5.（第一作者） 2015

25)CuiL(崔理立)#, LiY#, Ma G, Wang Y, Cai Y, Liu S, Chen Y, Li J, Xie Y, Liu G, Zhao B, Li K.A functional polymorphism in the promoter region ofmicroRNA-146a is associated with the risk of Alzheimer disease and the rate ofcognitive decline in patients. PLoS One. 2014 Feb 25; 9(2):e89019.（第一作者）2014

26)Cui L(崔理立)#, Huang X#, Wang J, Zhang Y.Specific and efficient anti- Aβ42 antibodies induced by sixteen tandem repeatsof Aβ9. Journal of Neuroimmunology.2010 227, 18–25. （第一作者）2010

27)HeJ, Chen Y, Lin Y, Zhang W, Cai Y, Chen F, Liao Q, Yin Z, Wang Y, Tao S, Lin X,Huang P, Cui L*(崔理立) , ShaoY*. Association study of MCP-1 promoterpolymorphisms with the susceptibility and progression of sepsis. PLoSOne. 2017 May 4;12(5):e0176781. (并列通讯作者) 2017

28)ZhaoJ, Tao H, Xian W, Cai Y, Cheng W, Yin M, Liang G, Li K, Cui L*(崔理立) , ZhaoB*. A Highly Selective Inhibitor of GlycineTransporter-1 Elevates the Threshold for Maximal Electroshock-Induced TonicSeizure in Mice. Biol Pharm Bull. 2016;39(2):174-80. (并列通讯作者) 2016

29)ShaoY, Li J, Cai Y, Xie Y, Ma G, Li Y, Chen Y, Liu G, Zhao B, Cui L*(崔理立), LiK*. The functional polymorphisms of miR-146aare associated with susceptibility to severe sepsis in the Chinese population.Mediators Inflamm. 2014:916202. (并列通讯作者) 2014

30)LiY, Yang C, Ma G, Gu X, Chen M, Chen Y, Zhao B, Cui L*(崔理立), LiK*. Association of polymorphisms of thereceptor for advanced glycation end products gene with COPD in the Chinesepopulation. DNA Cell Biol. 2014 Apr; 33(4):251-8. (并列通讯作者) 2014

31)TaoH#, Cui L(崔理立) #, LiY, Zhou X, Ma G, Yao L, Fu J, Li W, Cai Y, Zhou H, Zhong W, Zhang S, Xu Z, LiK, Zhao B. Association of Tag SNPs and Rare CNVs ofthe MIR155HG/miR-155 Gene with Epilepsy in the Chinese Han Population. BiomedRes Int. 2015; 2015:837213. （并列第一作者）2015

32)Li Y#, Cui L(崔理立)#, Li QQ, Ma GD, Cai YJ, Chen YY, Gu XF, Zhao B, Li KS. Associationbetween ADAM17 promoter polymorphisms and ischemic stroke in a Chinesepopulation. J Atheroscler Thromb. 2014;21(8):878-93.（并列第一作者）2014

专利

（1） miR-122及其抑制剂在预防/治疗放射性脑损伤中的应用。申请号：202010479483.3申请日：2020-05-29。申请人：崔理立，周海红，孙芙蓉，欧铭乾。

（2）一种治疗阿尔茨海默病的microRNA及其应用。申请号：201710828954.5申请日：2017-09-14。申请人：崔理立，赵斌，麦晖，李晓慧，蔡玉洁。

（3）EGR-1基因在制备治疗脓毒症药物中的用途及相关药物。申请号：201811196610.8申请日：2018-10-15。申请人：崔理立，陈风，邵义明，张文莹，赵田，卢芙蓉。

（4）一种用于治疗阿尔茨海默氏病的抗原多肽及多肽基因。国别：中国。授权日:2012.06.27。授权号: CN101481421 B。作者：张应玖，王嘉鹏，崔理立。

（5）一种用于治疗阿尔茨海默氏病的抗原蛋白及蛋白基因。国别：中国。授权日:2012.05.30。授权号: CN101486768 B。作者：张应玖，黄雪媚，崔理立。

近五年承担科研项目：

1．AD早期海马区神经元中Sirtuin2胞浆富集介导APP代谢改变的机制(82071190)。国家自然科学基金面上项目，55万。2021.01-2024.12，在研

2．APOE基因多态性通过调节神经炎症反应应答敏感性影响AD易感性的作用机制研究（81671181）.国家自然科学基金面上项目，57万。2017.01-2020.12，在研

3．MicroRNA靶向SIRT2 对α- 突触核蛋白聚集状态的影响及其靶点多态性与帕金森病的关联研究（81401061）。国家自然科学基金青年项目         22万。2015.01-2017.12，结题

4．广东省“扬帆计划”培养高层次人才项目，广东省教育厅，20万。2017.03-2020.03，结题

5．载脂蛋白E调控microRNA 对AD中星形胶质细胞炎症应答的机制研究（2017A030307039）。广东省科技发展专项资金-粤东西北创新人才联合培养项目，10万。2017.05-2020.05，结题。